The US Food and Drug Administration (FDA) has approved lisdexamfetamine, a drug used in treating teenage attention deficit hyperactivity disorder (ADHD). The approval came after a 4 week long dosage test on 314 teenagers.

The recommended initial dose of Lisdexamfetamine dimesylate capsule for new patients or the ones switching over to this is only 30 mg in the morning. This can be subsequently increased in the increments of 10 or 20. The maximum dosage is 70mg a day. "This adolescent indication for Vyvanse is good news for kids in this age group diagnosed with ADHD and their caregivers as it offers an additional treatment option to help them manage their symptoms," said Mike Yasick, senior vice president of Shire's ADHD Business. This medicine comes in the dosages of 30, 50 and 70 mg.

This medicine is safe for use in adolescents aged 13-17 years. Like many other psychiatric drugs, this prescription medication comes with a warning. Lisdexamfetamine Over dose can cause sudden death or serious cardiovascular problems. It has a potential to cause addiction and the drug should not be taken without medical consultation.

As this can be subjected to misuse, the agency recommends its safe storage. Unauthorized selling or giving away of this medicine is against the law. FDA approval of lisdexamfetamine usage in teenagers aged 13-17 came after randomized, forced escalation study which showed considerable improvement in the patients after the administration of various dosages of lisdexamfetamine. This drug has been effectively used to treat ADHD in children aged between 6-12 years and in adults.